AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
EMA lifts restriction on Valneva's chikungunya vaccine for those over 65.
ByAinvest
Friday, Jul 11, 2025 11:40 am ET1min read
The European Medicines Agency (EMA) has lifted the temporary restriction on vaccinating people over 65 with Valneva's single-dose chikungunya vaccine IXCHIQ after a thorough review. The EMA concluded that the vaccine should be given with caution, especially in people with underlying medical conditions. IXCHIQ is contraindicated for those with weakened immune systems.
The European Medicines Agency (EMA) has lifted the temporary restriction on vaccinating people over 65 with Valneva SE's single-dose chikungunya vaccine IXCHIQ®. The decision follows a thorough review by EMA's safety committee (PRAC) which concluded that the vaccine should be given with caution, especially in people with underlying medical conditions. The committee noted that IXCHIQ® is contraindicated for individuals with weakened immune systems.The review was initiated in May following reports of serious side effects in elderly individuals with several underlying medical conditions. EMA emphasized that IXCHIQ® should be administered when there is a significant risk of chikungunya infection, and after careful consideration of the benefits and risks. The vaccine is already contraindicated for people with weakened immune systems.
IXCHIQ® was authorized in the European Union in June 2024 and received a label extension for adolescents aged 12 and above in March 2025. Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs. Their pipeline includes vaccines against chikungunya, Lyme disease, Shigella, and Zika virus, among others.
The chikungunya virus is a mosquito-borne disease that causes fever, severe joint and muscle pain, headache, nausea, fatigue, and rash. Joint pain can be debilitating and persistent. Since 2004, chikungunya has caused large-scale outbreaks worldwide, with over 3.7 million cases reported in the Americas between 2013 and 2023 [1].
Valneva SE's stock is listed on Nasdaq (VALN) and Euronext Paris (VLA). The company's revenues from its growing commercial business help fund the advancement of its vaccine pipeline.
References:
[1] https://finance.yahoo.com/news/valneva-announces-lifting-european-medicines-153500263.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet